Addex Therapeutics annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
Addex Therapeutics EBITDA Growth & History (ADXN)
Addex Therapeutics's calculated EBITDA was −CHF6.8M for fiscal 2025.
View full Addex Therapeutics company overviewAddex Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −CHF6.8M | −CHF4.5M | — |
| 2024 | 2024-12-31 | −CHF2.4M | −CHF148,972 | — |
| 2023 | 2023-12-31 | −CHF2.2M | CHF8.3M | — |
| 2022 | 2022-12-31 | −CHF10.5M | CHF4.6M | — |
| 2021 | 2021-12-31 | −CHF15.2M | −CHF3.3M | — |
| 2020 | 2020-12-31 | −CHF11.9M | CHF2.4M | — |
| 2019 | 2019-12-31 | −CHF14.3M | −CHF12.8M | — |
| 2018 | 2018-12-31 | −CHF1.4M | CHF1.8M | — |
| 2017 | 2017-12-31 | −CHF3.2M | — | — |
Addex Therapeutics quarterly ebitda
Q2.21
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | −CHF1.7M | −CHF230,766 | — |
| Q4 2025 | 2025-12-31 | −CHF1.8M | — | — |
| Q3 2025 | 2025-09-30 | −CHF1.6M | — | — |
| Q2 2025 | 2025-06-30 | −CHF730,780 | CHF56,154 | — |
| Q1 2025 | 2025-03-31 | −CHF1.5M | — | — |
| Q2 2024 | 2024-06-30 | −CHF786,934 | CHF1.7M | — |
| Q2 2023 | 2023-06-30 | −CHF2.5M | CHF4.5M | — |
| Q2 2022 | 2022-06-30 | −CHF7.0M | −CHF2.6M | — |
| Q2 2021 | 2021-06-30 | −CHF4.4M | — | — |
Addex Therapeutics ebitda trends
Over the last five fiscal years, Addex Therapeutics's ebitda increased from −CHF11.9M to −CHF6.8M, a change of CHF5.0M. The latest reported quarter, Q1 2026, shows −CHF1.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Addex Therapeutics source filings ↗Community posts
Addex reports limited cash as half-year loss reaches CHF3.46 million
Addex Therapeutics ($ADXN) reported a first-half net loss of CHF3.46 million, compared with CHF3.31 million a year earlier. Its operating loss narrowed to CHF1.13 million, but the share of losses from associates increased to CHF2.33 million ...
